INBRAIN Neuroelectronics is a clinical-stage neurotechnology company developing precision brain-computer interface therapeutics powered by graphene. Its platform uses graphene neural interfaces for ultra-precise, adaptive and biocompatible neuromodulation aimed at Parkinson’s disease, epilepsy, stroke rehabilitation and future neuropsychiatric indications. The technology combines advanced neural decoding and micrometric modulation with AI-driven real-time monitoring to deliver personalized, adaptive treatments that seek to improve outcomes and reduce side effects. INBRAIN was awarded a €4 million grant by the Spanish Ministry of Industry and Tourism through the PERTE Chip initiative to accelerate development of its graphene-based BCI technology. The company has received FDA Breakthrough Device Designation for its BCI-Tx in Parkinson’s disease. INBRAIN is collaborating with partners including Merck KGaA and its subsidiary INNERVIA Bioelectronics to expand applications to peripheral nerve and systemic diseases and to advance its commercialization and clinical programs. INBRAIN Neuroelectronics builds a graphene-based, AI-driven BCI‑Tx platform that combines advanced neural decoding and micrometric modulation to deliver personalized treatments for neurological conditions. Its implantable graphene interfaces are ~10 micrometers thick and designed to decode and modulate neural activity with high resolution. The company has an ongoing clinical trial and reported the world’s first human application of its graphene BCI at Salford Royal Hospital in Manchester. Funding will support ongoing clinical trials, team expansion, commercialization efforts, and further development of its AI platform. INBRAIN has received FDA Breakthrough Device Designation for its BCI‑Tx in Parkinson’s disease and is collaborating with partners such as Merck KGaA and imec to translate and scale its technology. INBRAIN Neuroelectronics builds graphene-based neural interfaces intended to detect more biomarkers with less invasive procedures and to modulate brain activity for personalized therapies. The company combines its hardware with artificial intelligence and big data to read and trigger responses in the brain. Its technology is aimed at treating central nervous system conditions such as Parkinson’s disease, epilepsy and speech disorders. INBRAIN is a spin-off of the Institut Català de Nanociència i Nanotecnologia (ICN2) and ICREA. Over the past four years the company has secured €52 million in investment. It is advancing clinical development of its R&D programs and preparing a new financing round to be announced next year. INBRAIN Neuroelectronics is a medical device company building an intelligent graphene-brain interface that combines less-invasive graphene electrodes with machine learning software to detect therapy-specific biomarkers and deliver personalized neuromodulation. Its first product is designed to read and modulate brain activity for adaptive therapy targeting epilepsy and Parkinson’s disease. The company emphasizes graphene’s unique electrical and thermal conduction properties to enable ultra-high signal resolution. INBRAIN plans to advance a first-in-human clinical program to establish the safety of graphene-based neurotechnology and move toward making graphene a new standard of care. The company was founded in 2019 and is based in Barcelona, Spain. Financially, INBRAIN announced a $16.8 million Series A to fund these clinical and development efforts. Inbrain Neuroelectronics is a spin-off of the Institut Català de Nanociència i Nanotecnologia (ICN2) that develops graphene-based brain implants for treating neurological diseases such as Parkinson’s disease and epilepsy. Its core product is a graphene neural implant designed to interface with the brain for therapeutic and diagnostic applications. The company targets a large addressable market cited at €3.5 billion. Inbrain operates in the medical instruments sector and is based in Sant Just Desvern (Barcelona). In June 2020 it closed a €1 million venture capital financing led by Sabadell-Asabys (managed by Asabys Partners) and Alta Life Sciences. No operating metrics or revenue figures were disclosed in the article.

Total raised

$94M

Funding rounds

5

Latest round

Grant

Latest activity

May 2025